I am hoping that the good news break point will be before there is a 30 million outstanding share point considering existing, preferred and warrants. I hope they release a positive report soon on the latest evaluations. However, it is a little unrealistic to expect that soon on the latest higher dosage transplantations. I am extremely glad they made it to phase I and II human trials. The primate studies where significant and through extremely reputable entities. They showed positive efficacy, but there is nothing like being able to talk to a patient and discuss exactly how they are feeling.
Again, best of luck everywhere.
Wishing you the best of good buys,
HS
Market Data 
Markets 
AI
